The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
Open accessAbstract
Evidence suggests that Alzheimer disease (AD) begins as a disorder of synaptic function, caused in part by increased levels of amyloid beta-peptide 1-42 (Abeta42). Both synaptic and cognitive deficits are reproduced in mice double transgenic for amyloid precursor protein (AA substitution K670N,M671L) and presenilin-1 (AA substitution M146V). Here we demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates deficits in both long-term potentiation (LTP) and contextual learning in the double-transgenic mice. Most importantly, this beneficial effect can be extended beyond the duration of the administration. One course of long-term systemic treatment with rolipram improves LTP and basal synaptic transmission as well as working, reference, and associative memory deficits for at least 2 months after the end of the treatment. This protective effect is possibly due to stabilization of synaptic circuitry via alterations in gene expression by activation of the cAMP-dependent protein kinase (PKA)/cAMP regulatory element-binding protein (CREB) signaling pathway that make the synapses more resistant to the insult inflicted by Abeta. Thus, agents that enhance the cAMP/PKA/CREB pathway have potential for the treatment of AD and other diseases associated with elevated Abeta42 levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tg-mouse AD models manifest a spontaneous age-onset impairment of LTP (Gong et al., 2004) that presumably is linked to impaired performance in memory tests (Arendash et al., 2001).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486
Flagged first, then by citations
Research works printed but not linked: 2
- Masliah, 1995, Histol. Histopathol., 10, 509
- 10.1073/pnas.95.25.15020 · DOI
Cited by
Sorted by citations
Items 401–452 of 452
Compartmentalization and Regulation of Cyclic Nucleotide Signaling in The CNS
Zaccolo, M., & Stangherlin, A. (2014) · Wiley eBooks · doi:10.1002/9781118836507.ch03 · Cited by 1
Luyben, T. T. (2018) · TSpace (University of Toronto) · Cited by 1
Multicolour optogenetics for studying the roles of cAMP and cGMP in synaptic plasticity and memory
Valencia, M. (2018) · TSpace (University of Toronto) · Cited by 1
Neuroinflammation – PDE Family Inhibitors in the Regulation of Neuroinflammation
Mizuno, T. (2008) · Springer eBooks · doi:10.1007/978-3-540-29678-2_3867 · Cited by 1
Inhibition of Cyclic Nucleotide Phosphodiesterases to Regulate Memory
Zhang, H., Xu, Y., & O’Donnell, J. M. (2014) · doi:10.1002/9781118836507.ch07
Regulation of synaptic function and plasticity by cyclin-dependent kinase 5
Su, S. C. (2012) · DSpace@MIT (Massachusetts Institute of Technology)
The effects of phosphodiesterase inhibition on memory
Rutten, K. (2007) · doi:10.26481/dis.20070530kr
Enhanced cGMP-dependent signaling in astrocytes: Novel therapeutic target for Alzheimer’s Disease
Woart, N., Winkler, J., Ma, H., & White, R. E. (2015) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Can PDE inhibition improve cognition? : Translational insights
Reneerkens, O. A. H. (2013) · doi:10.26481/dis.20130418or
Costa, D. A. (2005) · Digital Commons - University of South Florida (University of South Florida)
Brain-TargetedProanthocyanidinMetabolitesfor Alzheimer'sDiseaseTreatment
NaganaGowda, G. A. (2012)
INIBIDORES DAS FOSFODIESTERASES DOS NUCLEÓTIDOS CÍCLICOS NA TERAPÊUTICA FARMACOLÓGICA
Morgado, S., Morgado, M., & Costa, I. M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.25756/rpf.v4i2.71
4-(3-Cyclopentoxy-4-[11C]methoxy-phenyl)pyrrolidin-2-one
Leung, K. (2008) · Europe PMC (PubMed Central)
Coregulators in Metabolic and Neurodegenerative Diseases
Feige, J. N., Yamamoto, H., & Auwerx, J. H. (2008) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812819178_0009
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_2
“CREB-mediated gene expression is impaired in the brains of both AD mouse models and patients (Gong et al. 2004 ; Phillips et al. 1991 ), as well as in cultured neurons insulted with Aβ (Tong et al. 2001 ).”
BackgroundDas Gedächtnis und die biologische Basis der Individualität
Squire, L. R., & Kandel, E. R. (2009) · Spektrum Akademischer Verlag eBooks · doi:10.1007/978-3-8274-2168-5_10
Mehan, S., Nain, V. S., Meena, H., Sharma, D., Sankhla, R., & Singh, M. (2010) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.69580/76p3r855
Cy CliC AMP-sPeC ifiC PDes: A ProM ising ther APeutiC tA rget for Cns
Ghosh, M., & Pearse, D. D. (2010)
Yougbaré, I. (2010) · Serveur des thèses de l'Université de Strasbourg (University of Strasbourg)
Transcriptional Control of Nerve Cell Death, Survival and Repair
Cameron, R., & Dragunow, M. (2006) · Springer eBooks · doi:10.1007/978-0-387-33604-6_12
Effects of anle138b treatment on amyloid-β neurotoxicity
Thomas, C. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8233
Phosphodiesterase Inhibitors: A Therapeutic Augmentation for Treatment of Cognitive ImpairmentPreprint
Sharma, A., Goyal, A., & Garabadu, D. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3370129
Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia
Siuciak, J. A., & Pitts, W. J. (2012) · doi:10.1002/9781118309421.ch4
(2008) · Springer eBooks · doi:10.1007/978-3-540-29678-2_14
Paes, D. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231117dp
Català-Solsona, J., Lutzu, S., Lituma, P. J., Fábregas, C., Siedlecki‐Wullich, D., Giménez‐Llort, L., Miñano-Molina, A. J., Saura, C. A., Castillo, P. E., & Rodrı́guez-Álvarez, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.24.577010
From Molecules to Computational Modeling
Zhang, Y., Smolen, P. D., & Byrne, J. H. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190069162.013.11
Amyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease
Adeniji, A. O., Johnson, C., & Mody, V. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00020-x
Introduction to microglial aging and its involvement in neurodegenerative diseases
Ben-Azu, B., Gargus, M., Verkhratsky, A., & Tremblay, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00007-3
Huang, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118960
Anchored kinase and phosphatase signaling networks in amyloid β-induced synaptic dysfunction
Koek, L. A., Jo, H.-N., Kennedy, M. J., & Dell’Acqua, M. L. (2026) · Molecular Pharmacology · doi:10.1016/j.molpha.2026.100141
“183,184 185 also causes undesirable systemic effects including increased heart rate and blood pressure, nausea, and vomiting.”
Tropea, M. R., Aceto, G., Trovato, R. C., Nicitra, E., Santuccio, N., Intili, G., D’Ascenzo, M., & Puzzo, D. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1840697
“For example, phosphodiesterase inhibitors efficiently rescue impaired plasticity but produce little or no additional potentiation following strong tetanic stimulation protocols that already induce near-maximal levels of LTP (Gong et al., 2004; Vecsey et al., 2009).”
Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors
Noto, N. M., Martin, K., Fidelia, S., Parmar, M. S., Cubeddu, L. X., Gurusamy, N., & Speth, R. C. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109090
Aggregation and propagation of TAF15 trigger neurodegeneration
Meng, L., Liu, C., Gong, H., Gao, Y., Li, M., Liu, H., Teng, H., Xiong, M., Liu, H., Yan, M., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.06.022
Distinct roles of AMPA receptor subunits as potential therapeutic targets in Alzheimer’s disease
Seo, J., Kim, K., & Park, M. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108394
Huang, X., Wang, J., Guo, W., Ye, W., Hu, X., Zhou, X., Xu, B., Cheng, A., & Qian, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108421
BindingDB Entry 50012720: Advances in the Development of Phosphodiesterase-4 Inhibitors.
BindingDB (2022) · UC San Diego · doi:10.7270/q2w95dvv
BindingDB (2020) · UC San Diego · doi:10.7270/q22b91mk
Impact of stress exposure and pharmacological intervention on a mouse model of Alzheimer’s disease
Sierksma, S. R. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20121220ss
Metadata
- Authors
- Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Columbia University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2004-12-01
- Volume
- 114
- Issue
- 11
- Pages
- 1624-1634
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC529285
- OpenAlex
- W2034986487
- Cited by
- 442
- References
- 60
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 16 · 2023: 15 · 2022: 11 · 2021: 13 · 2020: 21 · 2019: 20 · 2018: 17 · 2017: 33 · 2016: 17 · 2015: 20 · 2014: 28 · 2013: 23 · 2012: 23
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- University of Minnesota
- York University
- National Institutes of Health
- School of Medicine, New York University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, rolipram, amyloid-beta 42, synaptic plasticity, long-term potentiation, contextual learning, memory impairment, phosphodiesterase-4 inhibitors, cAMP/PKA/CREB signaling, synaptic transmission, APP/PS1 double transgenic mice
- MeSH terms
- Alzheimer Disease, Animals, Cognition, Disease Models, Animal, Hippocampus, Humans, Learning, Male, Membrane Proteins, Mice, Transgenic, Synaptic Transmission, Phosphodiesterase Inhibitors, Amyloid beta-Protein Precursor, Cyclic AMP Response Element-Binding Protein, Long-Term Potentiation, Rolipram, Mice, Presenilin-1, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
